Terns Data from Ongoing Phase 1 Study of Allosteric BCR-ABL Inhibitor in leukemia

 Ability to dose TERN-701 without regard to food represents a key potential differentiator within the allosteric BCR-ABL inhibitor class

Pharmacokinetic data show no clinically significant difference in exposure between fed and fasted dosing

Phase 1 CARDINAL trial evaluating TERN-701 in 2L+ CML patients remains ongoing, with interim data from initial cohorts anticipated in second half of 2024

https://www.globenewswire.com/news-release/2024/04/29/2871639/0/en/Terns-Pharmaceuticals-Announces-Data-from-Ongoing-Phase-1-Pharmacokinetic-Study-of-Allosteric-BCR-ABL-Inhibitor-TERN-701-in-Adult-Healthy-Volunteers-and-Highlights-Potential-for-Co.html